In a move poised to reshape the maternal health technology landscape, Laborie Medical Technologies announced plans to acquire the JADA System, a postpartum uterine bleeding device developed by Organon, for up to $465 million.

The acquisition, unveiled Friday and guided by Simpson Thacher & Bartlett LLP and Cooley LLP, includes an upfront payment of $440 million and an additional $25 million contingent on 2026 revenue milestones.

A Lifesaving Device Goes Global

The JADA System, cleared by the U.S. Food and Drug Administration (FDA), is designed to control and treat abnormal postpartum uterine bleeding or hemorrhage — one of the leading causes of maternal mortality. The device is already available in over 2,000 U.S. hospitals and has reached more than 20 countries.

Headquartered in Portsmouth, New Hampshire, Laborie specializes in medical technology across urology, gastroenterology, and obstetrics, supported by capital markets powerhouse Patricia Industries.

“Childbirth is one of the most personal and profound moments in a woman’s life, and every mother deserves to feel supported throughout it,” said Chris Smith, Laborie’s President and CEO. “The JADA System helps care teams provide treatment when it matters most. We are proud to carry this mission forward and excited to welcome the talented JADA team to accelerate our growth in the obstetrics market.”

Organon’s Strategic Exit

According to Organon, approximately 100 employees working on the JADA System will transition to Laborie as part of the deal. Organon had first acquired the technology in June 2021, and now plans to use the net proceeds from the divestment to reduce debt.

“I am incredibly proud of the work the JADA team and Organon have done to help more than 136,000 mothers in over 20 countries,” said Joseph Morrissey, Organon’s interim CEO. “This transaction places JADA in the hands of a leading innovator, well-positioned to expand access and improve maternal outcomes worldwide.”

Legal Teams Behind the Deal

Laborie’s acquisition was steered by a skilled counsel team. The Simpson Thacher team was led by M&A partners Michael Holick and Keegan Lopez, executive compensation partner Jeannine McSweeney, and healthcare partner Vanessa Burrows.

Meanwhile, the Cooley LLP team included partners Mika Reiner Mayer and Charity Williams. Counsel for Organon has not yet been disclosed.

With this acquisition, Laborie strengthens its commitment to advancing maternal care — turning a life-saving device into a global symbol of innovation and compassion.